✦ LIBER ✦

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma

✍ Scribed by Hyun Young Woo; Si Hyun Bae; Jun Yong Park; Kwang Hyub Han; Ho Jong Chun; Byung Gil Choi; Hyeon U. Im; Jong Young Choi; Seung Kew Yoon; Jae Youn Cheong; Sung Won Cho; Byoung Kuk Jang; Jae Seok Hwang; Sang Gyune Kim; Young Seok Kim; Yeon Seok Seo; Hyung Joon Yim; Soon Ho Um; Korean Liver Cancer Study Group

Publisher: Springer
Year: 2009
Tongue: English
Weight: 385 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1126-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Repetitive short-course hepatic arterial

Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma

✍ Jun Yong Park; Sang Hoon Ahn; Young Joon Yoon; Ja Kyung Kim; Hyun Woong Lee; Do 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

## Abstract ## BACKGROUND. Hepatic arterial infusion chemotherapy (HAIC) has often been selected as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). The objective of the current study was to evaluate the efficacy and safety of repetitive HAIC with high‐dose 5‐fluorou

A randomized study comparing standard ve

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma : Cancer and Leukemia Group B study 9181

✍ Nancy A. Dawson; Mark Conaway; Susan Halabi; Eric P. Winer; Eric J. Small; Diana 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## BACKGROUND. Megestrol acetate (MA) is a synthetic progestin with reported activity in both hormone-sensitive and hormone-refractory prostate carcinoma (HRPC). Based on limited data suggesting a possible dose-response effect, a trial was initiated to compare standard versus moderately high dose M

Combined hormonal therapy with high-dose

Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study

✍ Juan C. Cervellino; Carlos E. Araujo; Claudia Pirisi; Oscar Podskubka; Eduardo M 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB

Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A). In group B, patients were treated with DES-DP as in A, plus vindesine (VND) 3 mg/m2 int